TY - JOUR
T1 - Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia
AU - Miranti, Eugenia
AU - Ho, Dora Y.
AU - Enriquez, Kyle
AU - Subramanian, Aruna K.
AU - Medeiros, Bruno C.
AU - Epstein, David J.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Invasive fungal diseases (IFDs) are common in patients with acute myeloid leukemia (AML), but no recent data on incidence without antifungal prophylaxis are available. We evaluated the incidence of IFDs in patients with AML undergoing induction chemotherapy at Stanford University Hospital from 2012 to 2017, for up to 12 weeks after induction. We also analyzed factors associated with IFD development. Thirty-six of 240 patients (13%) developed at least one proven or probable IFD. Seventy-eight percent of the proven or probable IFDs were due to Candida or Aspergillus species. Infection due to Fusarium and Mucorales was uncommon. Absolute neutrophil count (ANC) of <500 µL/L at the start of induction was associated with an increased risk of IFD. One hundred and eighty-seven patients (78%) were started on systemic antifungal drugs, even without microbiologic evidence of an IFD. IFDs remain frequent in AML patients undergoing induction chemotherapy without antifungal prophylaxis.
AB - Invasive fungal diseases (IFDs) are common in patients with acute myeloid leukemia (AML), but no recent data on incidence without antifungal prophylaxis are available. We evaluated the incidence of IFDs in patients with AML undergoing induction chemotherapy at Stanford University Hospital from 2012 to 2017, for up to 12 weeks after induction. We also analyzed factors associated with IFD development. Thirty-six of 240 patients (13%) developed at least one proven or probable IFD. Seventy-eight percent of the proven or probable IFDs were due to Candida or Aspergillus species. Infection due to Fusarium and Mucorales was uncommon. Absolute neutrophil count (ANC) of <500 µL/L at the start of induction was associated with an increased risk of IFD. One hundred and eighty-seven patients (78%) were started on systemic antifungal drugs, even without microbiologic evidence of an IFD. IFDs remain frequent in AML patients undergoing induction chemotherapy without antifungal prophylaxis.
KW - Acute myeloid leukemia
KW - antifungal agents
KW - antifungal prophylaxis
KW - induction chemotherapy
KW - invasive fungal diseases
UR - https://www.scopus.com/pages/publications/85129202841
U2 - 10.1080/10428194.2022.2060504
DO - 10.1080/10428194.2022.2060504
M3 - Article
C2 - 35410569
AN - SCOPUS:85129202841
SN - 1042-8194
VL - 63
SP - 2206
EP - 2212
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -